Wednesday, February 22, 2017 5:56:41 PM
3)
Mr. Parliament is our chairman of the board of the directors, chief executive officer, president and a director. On October 3, 2016 Mr. Parliament returned 34,725,323 common shares to Bravo treasury for cancellation in exchange for a convertible promissory note with a face value of $1,128,573.00.
(4)
Mr. Wolfe is our chief financial officer, principal accounting officer, and treasurer. Mr. Wolfe declined to stand for reelection as director due to personal reasons. On October 3, 2016 Mr. Wolfe returned 6,422,547 common shares to Bravo treasury for cancellation in exchange for a convertible promissory note with a face value of $208,732.78.
(5)
Mr. Brooks is our vice president and a director. On October 3, 2016 Mr. Brooks returned 13,591,363 common shares to Bravo treasury for cancellation in exchange for a convertible promissory note with a face value of $441,719.29.
(6)
Mr. Kaiser is our secretary and corporate governance officer, and director. On October 3, 2016 Mr. Kaiser returned 3,050,329 common shares to Bravo treasury for cancellation in exchange for a convertible promissory note with a face value of $99,135.69.
(7)
Mr. Kosta has a Consulting Agreement with Bravo Multinational Incorporated. On October 3 and 11 Mr Kosta returned 1,122,997 and 5,333,334 common shares to Bravo treasury for cancellation in exchange for convertible promissory notes with a face value of $36,497.40 and $160,000.
Recent BRVO News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:36:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 08:24:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 09:12:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:36:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:15:48 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/19/2023 08:31:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 12:27:30 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/28/2023 08:11:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2023 08:02:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/07/2023 08:03:17 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM